Back to search results

Visual Communication Tool for Cancer Treatment Understanding

This study is testing a visual communication tool called MyCareGorithm. This tool will be used during your doctor's visit to help explain your cancer, its stage, and how radiation treatment works. The goal is to see if using MyCareGorithm can make patients, their caregivers, and healthcare providers more satisfied with the overall experience. You might be able to join if you are an adult (18-100 years old) with newly diagnosed breast or head and neck cancer, speak English, are being treated at NYU Langone Health, and are planning to receive definitive (curative) treatment. The study is currently unclear on its recruitment status and aims to enroll 86 participants. Success will be measured by the percentage of patients who report being "Satisfied" on the day of their consultation.

Study design
This study is an interventional study, meaning participants will receive an intervention (the MyCareGorithm tool). It plans to enroll 86 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, patient satisfaction, is measured on Day 0 (the day of consultation).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06927050

Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers

Recruiting
NAAges 18+InterventionalHealth services
NYU Langone Health
~86 participants
Updated 2026-02-25 on ClinicalTrials.gov
What's tested:Visual Communication Tool

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of "Satisfied" Patients
Measured over Day 0

Conditions

Cancer

Explore related trials

Breast CarcinomaMalignant Head and Neck Neoplasm

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Jason Domogauer, MD, PhD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Jason Domogauer, MD, PhD
[email protected]
(212) 501-5003
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients seen in consultation from 12/1/2024-6/1/2025
Patients aged 18 years to 100 years old
Patients with a malignancy of breast or head and neck
English speaking patients
Patients being treated with definitive intent
Patients treated at NYU Langone Health for their malignancy
Willing and able to provide consent
Willing and able to provide consent
Doctors and nurse practitioners in medical oncology and radiation oncology, and in the ear nose throat (ENT) department.
Willing and able to provide consent
aged 18 years to 100 years old

Exclusion

Patients with any other site of disease other than listed above
Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process.
Patient unable to complete the survey portion of the study independently

What this trial measures

  • Percentage of "Satisfied" PatientsDay 0

    Patients will take a 9-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; patients with 6 or more "Yes" answers out of 9 questions are defined as "Satisfied" patients.